Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00250562 · ClinicalTrials.gov registry record · Phase 3
A Study in Chinese Mild to Moderate Hypertensive Patients Comparing the Efficacy of Co-Diovan With Diovan.
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,171
- Enrollment target
NCT00250562 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 1,171 participants.
The verdict
NCT00250562, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,171 participants
- Enrollment target
Study Summary
Valsartan, an orally active angiotensin II receptor blocker, is registered in most countries worldwide for the treatment of hypertension. In China the usual recommended starting and maintenance dose is 80 mg o.d. The combination of HCTZ 12.5 mg with valsartan 80 mg has been shown to have additive effects in lowering blood pressure compared to valsartan 80 mg in patients not adequately controlled by valsartan 80 mg monotherapy5 or in non-selected patients6. This fixed combination is registered in most countries worldwide. The potential benefits of these combinations should be evaluated in patients not adequately controlled by valsartan 80 mg monotherapy. This study will compare the efficacy, safety and tolerability of adding HCTZ 12.5 mg to valsartan 80 mg in those hypertensive patients. This study is not recruiting in the US.
Interventions
- DRUG valsartan plus hydrochlorothiazide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,171 participants |
| Start Date | 2005-10 |
| Est. Completion | 2006-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00250562
The ClinicalTrials.gov registry entry for NCT00250562 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,171 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which valsartan plus hydrochlorothiazide is the first listed.
NCT00250562 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00250562 about?
NCT00250562 is a clinical study titled "A Study in Chinese Mild to Moderate Hypertensive Patients Comparing the Efficacy of Co-Diovan With Diovan.". Valsartan, an orally active angiotensin II receptor blocker, is registered in most countries worldwide for the treatment of hypertension. In China the usual recommended starting and maintenance dose is 80 mg o.d. The combination of HCTZ 12.5 mg with valsartan 80 mg has been shown to have additive ef...
What is the current status of trial NCT00250562?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,171 participants. The study started on 2005-10. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00250562?
The interventions under investigation include: valsartan plus hydrochlorothiazide (DRUG).
Who is sponsoring clinical trial NCT00250562?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.